Data compiled by Redley Lamar · ChainSifter Intelligence
3Suppliers
8Customers
2Debt Items
16Related Chains
Source-Backed Evidence Depth
Edgewise Therapeutics, Inc. (EWTX) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
14Total relationships
1Distinct source URLs
8High confidence
0.776Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Edgewise Therapeutics, Inc. Suppliers
Ticker
Name
Confidence
Evidence
LEERINK-PARTNERS-LLC
LEERINK-PARTNERS-LLC
90%
The Company may offer and sell shares of common stock, having aggregate sales proceeds of up to $ 175.0 million from time to time, through an “at the market offering” program (Leerink ATM) under whic…
SANTHERA
SANTHERA
80%
Catalyst Pharmaceuticals, Inc. has commercialized this product in the United States following its North America exclusive license deal with Santhera.
Reciprocal relationship from KROS graph: nued regulatory review, which may result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirement…
Edgewise Therapeutics, Inc. Customers
Ticker
Name
Confidence
Evidence
CATALYST-PHARMACEUTICALS-INC
CATALYST-PHARMACEUTICALS-INC
85%
In October 2023, the FDA granted AGAMREE (vamorolone) approval in Duchenne patients aged 2 years and older and Catalyst Pharmaceuticals, Inc. has commercialized this product in the United States foll…
NIPPON-SHINYAKU-CO-LTD
NIPPON-SHINYAKU-CO-LTD
85%
VILTEPSO (vitolarsen), a naked PMO approved for the treatment of Duchenne patients amenable to Exon 53 skipping, which is marketed by Nippon Shinyaku Co. Ltd.
SAREPTA-THERAPEUTICS-INC
SAREPTA-THERAPEUTICS-INC
85%
EXONDYS 51 (eteplirsen), AMONDYS 45 (casimersen) and VYONDYS 53 (golodirsen), which are naked phosphorodiamidate morpholino oligomers (PMOs) approved for the treatment of Duchenne patients amenable t…
Reciprocal relationship from KROS graph: Reciprocal relationship from EWTX graph: Reciprocal relationship from KROS graph: nued regulatory review, which may result in significant additional expense a…
CAPITAL-RESOURCES
CAPITAL-RESOURCES
62%
people with muscular dystrophy (LYNX, FOX, and GRAND CANYON, a potentially registrational, or pivotal cohort, in individuals with Becker as part of the CANYON trial), a multipart Phase 2 trial with E…
CATALYST-PHARMS-INC
CATALYST-PHARMS-INC
62%
om preclinical studies or clinical trials; ● we may be unable to demonstrate to the FDA, EMA or other comparable foreign regulatory authorities that our product candidate’s risk-benefit ratio for its…
LEERINK-PARTNERS-LLC
LEERINK-PARTNERS-LLC
62%
rough clinical development as product candidates in later stages of clinical development generally have higher development costs than those in earlier stages, primarily due to the increased size and …
NASDAQ-STOCK-MARKET-LLC
NASDAQ-STOCK-MARKET-LLC
62%
ime, we evaluate various acquisition opportunities and strategic partnerships, including licensing or acquiring complementary products, intellectual property rights, technologies or businesses. Any p…
Edgewise Therapeutics, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
EWTX-DEBT-9407
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2021-12-31.
EWTX-DEBT
Debt stack $66,000
90%
Market cache reports total debt of $66,000.
Edgewise Therapeutics, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Edgewise Therapeutics, Inc..
Edgewise Therapeutics, Inc. Ownership
Holder
Name
Confidence
Evidence
EWTX-OWNER-ORBIMED-ADVISORS-LLC
ORBIMED ADVISORS LLC
90%
13F overlay lists ORBIMED ADVISORS LLC as top holder; 218 tracked holders.
Edgewise Therapeutics, Inc. Extended Supply Chain Network
